|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4957735A
(en)
|
1984-06-12 |
1990-09-18 |
The University Of Tennessee Research Corporation |
Target-sensitive immunoliposomes- preparation and characterization
|
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
US5055303A
(en)
|
1989-01-31 |
1991-10-08 |
Kv Pharmaceutical Company |
Solid controlled release bioadherent emulsions
|
|
US5271961A
(en)
|
1989-11-06 |
1993-12-21 |
Alkermes Controlled Therapeutics, Inc. |
Method for producing protein microspheres
|
|
US5188837A
(en)
|
1989-11-13 |
1993-02-23 |
Nova Pharmaceutical Corporation |
Lipsopheres for controlled delivery of substances
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
US5254342A
(en)
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
|
AU668384B2
(en)
|
1992-03-12 |
1996-05-02 |
Alkermes Controlled Therapeutics, Inc. |
Controlled release ACTH containing microspheres
|
|
US5534496A
(en)
|
1992-07-07 |
1996-07-09 |
University Of Southern California |
Methods and compositions to enhance epithelial drug transport
|
|
US5514670A
(en)
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
|
UA76977C2
(en)
|
2001-03-02 |
2006-10-16 |
Icos Corp |
Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
|
|
WO2002090360A1
(en)
|
2001-05-10 |
2002-11-14 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
WO2003010444A1
(en)
|
2001-07-23 |
2003-02-06 |
Shock-Proof Solutions Pty Ltd |
Mechanical shock absorbing apparatus
|
|
MXPA06000933A
(es)
|
2003-07-25 |
2006-03-30 |
Pfizer |
Compuestos de aminopirazol y uso como inhibidores de chk1.
|
|
US7163939B2
(en)
|
2003-11-05 |
2007-01-16 |
Abbott Laboratories |
Macrocyclic kinase inhibitors
|
|
US20050176733A1
(en)
|
2004-01-20 |
2005-08-11 |
Millennium Pharmaceuticals, Inc. |
Chk-1 inhibitors
|
|
JP2008505112A
(ja)
|
2004-07-02 |
2008-02-21 |
イコス・コーポレイション |
Ｃｈｋ１の阻害に有用な化合物
|
|
AU2005272586A1
(en)
|
2004-08-19 |
2006-02-23 |
Icos Corporation |
Compounds useful for inhibiting CHK1
|
|
HRP20100678T1
(hr)
*
|
2005-03-29 |
2011-02-28 |
Icos Corporation |
Derivati heteroariluree korisni kao inhibitori chk1
|
|
AR060635A1
(es)
|
2006-04-27 |
2008-07-02 |
Banyu Pharma Co Ltd |
Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
|
|
EA200901133A1
(ru)
|
2007-03-20 |
2010-04-30 |
Смитклайн Бичем Корпорейшн |
Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
|
|
ES2608940T3
(es)
|
2007-06-15 |
2017-04-17 |
Msd K.K. |
Derivado de bicicloanilina
|
|
PA8850801A1
(es)
|
2008-12-17 |
2010-07-27 |
Lilly Co Eli |
Compuestos útiles para inhibir chk1
|
|
EP2401281A4
(en)
|
2009-02-25 |
2012-08-15 |
Msd Kk |
PYRIMIDINPYRIMIDOINDAZOLDERIVAT
|
|
GB201008005D0
(en)
|
2010-05-13 |
2010-06-30 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
ES2621857T3
(es)
*
|
2010-11-16 |
2017-07-05 |
Array Biopharma, Inc. |
Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
|
|
TWI532742B
(zh)
|
2011-02-28 |
2016-05-11 |
艾伯維有限公司 |
激酶之三環抑制劑
|
|
US8716297B2
(en)
|
2011-07-15 |
2014-05-06 |
Abbvie Inc. |
Chemical entities to be used for Wee1 inhibition for the treatment of cancer
|
|
WO2013013031A1
(en)
|
2011-07-19 |
2013-01-24 |
Abbvie Inc. |
Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
|
|
EP2755482B1
(en)
*
|
2011-09-15 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Combination of mk-1775 and mk-8776 for treating cancer
|
|
US9181239B2
(en)
|
2011-10-20 |
2015-11-10 |
Abbvie Inc. |
Pyridopyrimidinone inhibitors of kinases
|
|
GB201119799D0
(en)
|
2011-11-16 |
2011-12-28 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
CN104271576A
(zh)
|
2012-02-23 |
2015-01-07 |
艾伯维公司 |
激酶的吡啶并嘧啶酮抑制剂
|
|
RU2659786C2
(ru)
*
|
2012-05-15 |
2018-07-04 |
Кансер Ресёрч Текнолоджи Лимитед |
5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
|
|
GB201306610D0
(en)
|
2013-04-11 |
2013-05-29 |
Almac Discovery Ltd |
Pharmaceutical compounds
|
|
WO2015019037A1
(en)
|
2013-08-05 |
2015-02-12 |
Almac Discovery Limited |
Pharmaceutical compounds
|
|
GB201316024D0
(en)
|
2013-09-09 |
2013-10-23 |
Almac Diagnostics Ltd |
Molecular diagnostic test for lung cancer
|
|
GB201322602D0
(en)
|
2013-12-19 |
2014-02-05 |
Almac Discovery Ltd |
Pharmaceutical compounds
|
|
GB201402277D0
(en)
*
|
2014-02-10 |
2014-03-26 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
GB201512869D0
(en)
|
2015-07-21 |
2015-09-02 |
Almac Diagnostics Ltd |
Gene signature for minute therapies
|
|
WO2017216559A1
(en)
|
2016-06-14 |
2017-12-21 |
Almac Diagnostics Limited |
Predicting responsiveness to therapy in prostate cancer
|
|
GB201612095D0
(en)
|
2016-07-12 |
2016-08-24 |
Almac Discovery Ltd |
Pharmaceutical compounds
|
|
GB201612092D0
(en)
|
2016-07-12 |
2016-08-24 |
Almac Discovery Ltd |
Pharmaceutical compounds
|